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Abstract
We evaluated the dynamics of clinical symptoms of 2009 pan-
demic influenza A (H1N1) using a four-point scale sheet. The
most frequent symptoms were fever and cough. The sum of
symptom score was high during the first 4 days. Systemic symp-
toms peaked earlier, by day 2, and resolved faster than upper
respiratory symptoms and lower respiratory symptoms after
oseltamivir treatment. The lower respiratory symptoms resolved
slowly over 2 weeks. The 2009 pandemic influenza A (H1N1)
virus might involve primarily lower respiratory tract and could
be the main cause of pneumonia.
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The clinical spectrum of 2009 pandemic influenza A virus
infection is still being delineated, and both self-limited illness
and severe outcomes, including respiratory failure and death,
have been observed. The most frequently reported
symptoms were cough and sore throat. Nausea, diarrhoea
and dyspnoea have been less frequently reported but are still
common [1,2].
The 2009 H1N1 influenza was confirmed by means of a
PCR assay. The PCR was initially conducted in the reference
laboratory at the South Korean National Institute of Health
and later, as the number of patients dramatically increased
locally, at Chonbuk National University Hospital.
Upper respiratory symptoms were defined as rhinorrhoea,
sore throat and nasal congestion. Lower respiratory symp-
toms (LRS) were defined as cough and dyspnoea. Systemic
symptoms were defined as subjective fever, headache and
myalgia. Gastrointestinal symptoms were defined as nausea,
vomiting and diarrhoea [3]. The symptoms score was aver-
age, in the range 0–3. All subjects were asked to complete a
daily log at approximately the same time every morning to
document the severity of their influenza-related symptoms
on a four-point scale sheet [4].
During the evaluation period, 239 patients were diagnosed
with pandemic influenza A infection. Among them, 118
patients were admitted to the hospital and the remaining
121 were given oseltamivir and sent home to rest. Among
the 118 patients, 85 patients (‡9 years old), who filled out
the symptoms score completely, were analysed for the study.
Of the 85 patients studied, 57 (67.1%) were male. The mean
age, hospital stay and interval from the onset of symptoms
to oseltamivir administration were 23.4 ± 14.3 years,
5.7 ± 1.5 days and 2.3 ± 1.4 days, respectively. Among the
clinical manifestations, fever (91.9%) and cough (91.9%) were
the most frequent, followed by sore throat (69.8%), rhinor-
rhoea (64.0%), headache (60.5%), nasal congestion (55.8%),
myalgia (43.2%), diarrhoea (31.4%), nausea (24.4%), dyspnoea
(22.1%) and vomiting (15.1%). The duration of cough was the
longest, followed by myalgia and sore throat (Fig. 1). Regard-
ing the severity of symptoms, systemic symptoms peaked the
earliest (by day 2) and resolved faster than LRS and upper
respiratory symptoms (Fig. 2). The LRS resolved slowly over
many days. The gastrointestinal symptoms were mild and
short-lived.
The highly pathogenic avian H5N1 viruses replicate mainly
in the lower respiratory tract of humans and cause severe
pneumonia [5]. WHO warned that small subsets of patients
with pandemic influenza virus infection could rapidly develop
very severe progressive pneumonia [6]. Even with the admin-
istration of oseltamivir, the LRS score decreased slowly. This
finding implies that infection with the pandemic H1N1 virus
involves primarily the lower respiratory tract, as does the
H5N1 infection. Risk groups with any type of chronic lung
disease should be advised to do their best to protect them-
selves from the pandemic influenza virus.
Transparency Declaration
The authors declare no conflicting interests.
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
RESEARCH NOTE 10.1111/j.1469-0691.2010.03117.x
References
1. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team,
Dawood FS, Jain S, Finelli L et al. Emergence of a novel swine-origin
influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605–
2615.
2. Centers for Disease Control and Prevention (CDC). Swine-origin
influenza A (H1N1) virus infections in a school – New York City,
April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 470–472.
3. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and
disease in human influenza: a review of volunteer challenge studies.
Am J Epidemiol 2008; 167: 775–785.
4. Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of
an extract of North American ginseng containing poly-furanosyl-
pyranosyl-saccharides for preventing upper respiratory tract infec-
tions: a randomized controlled trial. CMAJ 2005; 173: 1043–1048.
5. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic
potential of swine-origin H1N1 influenza virus. Nature 2009; 459:
931–939.
6. Pandemic (H1N1) 2009; Geneva: World Health Organization.
Available at:http://www.who.int/csr/disease/swineflu/en/index.html (last
accessed 19 October 2009).
FIG. 1. The duration of clinical symptoms in
patients infected with 2009 pandemic
influenza A (H1N1). The bold vertical lines
mean median duration of clinical symptoms.
FIG. 2. The dynamics of clinical symptoms in
patients infected with 2009 pandemic influ-
enza A (H1N1).
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